---
title: "康臣药业集团有限公司 (01681.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01681.HK.md"
symbol: "01681.HK"
name: "康臣药业集团有限公司"
industry: "制药"
---

# 康臣药业集团有限公司 (01681.HK)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 港股市场 |
| Website | [www.chinaconsun.com](https://www.chinaconsun.com) |

## Company Profile

康臣药业集团有限公司是一家主要从事药品生产及销售业务的公司。该公司通过两个部门开展业务。康臣药业分部主要从事生产及销售现代中成药及医用成像对比剂业务。玉林制药分部主要从事生产及销售传统中成药业务。该公司的产品主要包括肾科药物、妇儿药物、对比剂、骨科药物、皮肤科药物、肝胆药物和其他。该公司主要在中国国内市场开展业务。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:09.000Z

**Overall: B (0.26)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 9 / 48 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 19.47% |  |
| Net Profit YoY | 20.82% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.41 |  |
| Dividend Ratio | 3.30% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16.29B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.54B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 25.06% | A |
| Profit Margin | 30.88% | A |
| Gross Margin | 77.06% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 19.47% | B |
| Net Profit YoY | 20.82% | B |
| Total Assets YoY | 13.05% | B |
| Net Assets YoY | 18.59% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 323.82% | C |
| OCF YoY | 19.47% | B |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.56 | B |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.74% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 康臣药业集团有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "25.06%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "30.88%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.06%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "19.47%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "20.82%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.05%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "18.59%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "323.82%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "19.47%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.74%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 恒瑞医药 (HK.1276) | A | B | C | A | B | B |
| 02 | 翰森制药 (HK.3692) | A | B | C | A | C | B |
| 03 | 中国生物制药 (HK.1177) | B | B | C | B | B | B |
| 04 | 康哲药业 (HK.867) | B | B | C | A | B | B |
| 05 | 先声药业 (HK.2096) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.72 | 18/51 | 12.29 | 11.37 | 8.31 |
| PB | 3.41 | 41/51 | 2.85 | 2.60 | 1.85 |
| PS (TTM) | 4.55 | 37/51 | 3.80 | 3.51 | 2.54 |
| Dividend Yield | 3.30% | 18/51 | 9.36% | 4.37% | 3.94% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-09-02T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 33% |
| Overweight | 2 | 67% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 19.36 |
| Highest Target | 22.04 |
| Lowest Target | 15.91 |

## References

- [Company Overview](https://longbridge.com/en/quote/01681.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01681.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01681.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.